Laurie H. Glimcher, MD
President and Chief Executive Officer
Laurie H. Glimcher, MD, is the President and CEO of Dana-Farber Cancer Institute, Director of the Dana-Farber/Harvard Cancer Center, and the Richard and Susan Smith Professor
of Medicine at Harvard Medical School. Previously, she was the Stephen and Suzanne Weiss Dean and Professor of Medicine of Weill Cornell Medicine and Provost for Medical Affairs of Cornell University. Dr. Glimcher is a distinguished immunologist,
widely renowned for her work in one of the most promising areas of cancer research.
Dr. Glimcher is a Member of the National Academy of Sciences, the National Academy of Medicine, and the American Philosophical Society; Fellow of the American Academy of Arts and Sciences; and former President of the American Association of Immunologists.
She is a member of the Cancer Research Institute, Prix Galien, Parker Institute for Cancer Immunotherapy, Repare Therapeutics, Abpro Therapeutics, Biosciences, Inc. Scientific Advisory Boards, the Lasker Award Jury, American Association for Cancer
Research, the Association of American Cancer Institutes, and the American Society of Clinical Oncology, and served on the Vice President's Blue Ribbon panel. She previously served on the Board of Directors of Bristol-Myers Squibb Pharmaceutical Corporation,
the Waters Corporation, and GSK plc. She currently serves as a consultant for the JPM Healthcare Advisory Committee and is on the Board of Directors of Analog Devices, Inc. She is also a member of the Board of Trustees of the Massachusetts Health
& Hospital Association and a member of the Board of Directors of the Broad Institute.
Dr. Glimcher's research identified key transcriptional regulators of protective immunity and the origin of pathophysiologic immune responses underlying autoimmune, infectious, and malignant diseases. Dr. Glimcher speaks nationally and internationally
on cancer, immunology, and translational medicine and has contributed more than 350 scholarly articles and papers to the medical literature.
Aside from her research efforts, Dr. Glimcher has been a staunch proponent of improved access to care, health policy, and medical education, while simultaneously serving as a pioneering mentor and role model for cancer research trainees and for all women
in science. Notably, she was the first female to be appointed as Dean of Weill Cornell Medicine in New York, and is the first female President and Chief Executive Officer of Dana-Farber Cancer Institute.
Dr. Glimcher is the recipient of many awards and honors. In 2022, she was named to Modern Healthcare's 50 Most Influential Clinical Executives. In 2018, she received the American Association of Immunologists Lifetime Achievement Award; the Indiana
University School of Medicine's Steven C. Beering Award for outstanding research contributions to the advancement of biomedical or clinical science; and the L'Oréal-UNESCO Award for Women in Science. She has also received the 2017 George M. Kober
Medal and the 2017 Award for Distinguished Research in the Biomedical Sciences from the Association of American Medical Colleges (AAMC).
Dr. Glimcher is a magna cum laude graduate of Radcliffe College, and holds an MD degree cum laude from Harvard Medical School.
Learn more about Laurie Glimcher, MD
William C. Hahn, MD, PhD
Executive Vice President and Chief Operating Officer
William C. Hahn, MD, PhD, has been engaged in clinical care and research at Dana-Farber since 1996. He is the William Rosenberg Professor of Medicine and an Institute Member of the Broad Institute of MIT and
Harvard. He received his AB in Biochemical Sciences, PhD in Immunology, and MD all from Harvard University and completed his clinical training at Massachusetts General Hospital and Dana-Farber Cancer Institute. His research focuses on understanding
how mutations cooperate in cancer initiation and progression to develop rational combination therapies.
Michael L. Reney
Executive Vice President and Chief Finance and Business Strategy Officer
Michael Reney joined Dana-Farber in 2015, and is responsible for treasury, accounting, business planning, revenue cycle, payer contracting, decision support, and population management. Mr. Reney also serves as Assistant Treasurer, Dana-Farber Cancer Institute,
Inc.; Assistant Treasurer, Dana-Farber, Inc.; Treasurer, The Dana-Farber Trust; and Treasurer, Dana-Farber Community Cancer Care Network. Prior to joining Dana-Farber, he served as Chief Financial Officer at Brigham and Women’s Hospital (BWH). Mr.
Reney began his career as a senior auditor at Deloitte & Touche, LLP, after which he joined BWH as its accounting manager. His extensive experience includes serving as assistant controller at Massachusetts General Hospital, followed by several positions
within Partners Healthcare. In 2000, he returned to BWH as controller and executive director of Finance, and was named Senior Vice President for Finance and Chief Financial Officer for BWHC in 2008.
Mr. Reney holds a Bachelor’s in Accounting from Bentley College and a Master’s in Business Administration from the University of Massachusetts, Boston. He is a member of the Healthcare Financial Management Association, as well as the Healthcare Roundtable
for CFOs. Additionally, he serves on the boards of the Medical Academic and Scientific Community Organization (MASCO) and Controlled Risk Insurance Company (CRICO).
Scott A. Armstrong, MD, PhD
President, Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Chair, Department of Pediatric Oncology
Scott A. Armstrong, MD, PhD, is president of the Dana-Farber/Boston Children's Cancer and Blood Disorders Center; chair of the Department of Pediatric Oncology at Dana-Farber
Cancer Institute; and the David G. Nathan Professor of Pediatrics. He also serves as associate chief of the Division of Hematology/Oncology at Boston Children’s Hospital. Dr. Armstrong was previously director of the Center for Epigenetics Research
at Memorial Sloan Kettering Cancer Center and Professor of Pediatrics at the Weill Cornell Medical College. He earned his medical degree and PhD from University of Texas Southwestern Medical School in 1996. After internship and residency training
with the Boston Combined Residency Program (BCRP) at Boston Medical Center and Boston Children’s Hospital, he completed a hematology/oncology fellowship at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center.
The major focus of Dr. Armstrong’s career has been on delineating the biology of childhood cancers and the development of new therapeutic approaches for children with cancer. His research program has focused on the mechanisms of leukemia development and
the relationship between leukemia and normal hematopoietic stem cells. Dr. Armstrong continues to direct a vigorous research program that focuses on development of new therapeutics that target chromatin-based mechanisms, and he is actively involved
in the development and translation of a number of new small molecule approaches that likely will be tested in clinical trials in the near future.
Bradley Bernstein, MD, PhD
Chair, Department of Cancer Biology
Bradley Bernstein, MD, PhD, is Chair of Cancer Biology at Dana-Farber, where he holds the Richard and Nancy Lubin Family Chair. He is also Director of the Gene Regulation Observatory at the Broad Institute;
a Professor of Cell Biology and Pathology at Harvard Medical School; and an Investigator in Harvard's Ludwig Institute.
Dr. Bernstein received his BS from Yale and his MD and PhD from the University of Washington, before completing a residency in clinical pathology at Brigham and Women's Hospital and postdoctoral research at Harvard University. He launched an independent
research program in the Department of Pathology at Massachusetts General Hospital and Harvard Medical School in 2005. Dr. Bernstein's honors include an Early Career Scientist Award from the Howard Hughes Medical Institute; a Career Award in the Biomedical
Sciences from the Burroughs Wellcome Fund; the NIH Director's Pioneer Award; an American Cancer Society Professorship; and the Paul Marks Prize for Cancer Research.
Craig A. Bunnell, MD, MPH, MBA
Chief Medical Officer
Craig A. Bunnell, MD, MPH, MBA, became the chief medical officer and medical director for Adult Ambulatory Oncology in 2012. Dr. Bunnell received his bachelor's degree, summa cum laude, from Colorado College
after which he was a Thomas J. Watson Fellow in Stockholm, Sweden. He earned his medical degree from Harvard Medical School and his MPH from the Harvard School of Public Health. He also earned his MBA from the Sloan School of Management at the Massachusetts
Institute of Technology. Dr. Bunnell completed his internship, residency and fellowship in hematology and oncology at Brigham and Women's Hospital, where he also served as chief medical resident. Dr. Bunnell is a medical oncologist involved in research
and the care of patients with breast cancer in the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute.
Kathleen Burns, MD, PhD
Chair, Department of Pathology
Kathleen Burns, MD, PhD, joined Dana-Farber in 2020 as the Chair of Pathology. She received her MD and PhD degrees from Baylor College of Medicine, and was recruited to Johns
Hopkins University School of Medicine for clinical pathology residency and hematopathology fellowship. Thereafter, she joined the faculty at Johns Hopkins, progressed through their academic ranks to Professor, and served as the pathology department's
Deputy Director (Vice Chair) for Research and Director of the institution's Physician Scientist Training Program (PSTP). Dr. Burns's research focuses on high copy number genomic repeats and transposable elements, their contributions to human disease,
and ways to leverage our understanding of their biology to treat cancers.
Senior Vice President and Chief People Officer
Heidi Conway joined Dana-Farber in July 2021. She brings deep experience in leading human resources initiatives that support employee development, engagement, mentorship, and well-being, and the growth of a diverse and inclusive workforce. Prior to joining
Dana-Farber, Ms. Conway was Vice President and Chief Human Resources Officer at the Johns Hopkins University.
During her tenure at Johns Hopkins, Ms. Conway was integral to strengthening and expanding the HR function, guiding her team and partnering with stakeholders across the institution to advance key strategic and operational initiatives for the university.
Among her many contributions are implementing a major expansion of JHU's child care benefits and paid parental leave for employees and students, strengthening HR talent across the function, enhancing the university's benefits program, and leading
a full review of the retirement and investment offerings with a focus on simplifying the employee experience.
Before joining Johns Hopkins, Ms. Conway held several HR leadership roles of increasing responsibility at Harvard University. She holds a B.A. in Business Administration from New England College and a master's in Administrative Studies from Boston College.
Senior Vice President for Research Operations
Michelle Cox joined Dana-Farber upon graduation from Assumption College in 1992. Ms. Cox is the Senior Vice President for Research Operations. Prior to this role, she served as the Department Administrator for Pediatric Oncology for over 15 years before
transitioning into Research Administration, where she held the positions of Senior Director for Shared Resources for Dana-Farber/Harvard Cancer Center and Vice President of Research Operations.
George D. Demetri, MD
Senior Vice President for Experimental Therapeutics
George D. Demetri, MD, advances institutional efforts in the discovery and development of novel anticancer therapies based on experience gained from his leadership in several drug development efforts, including
imatinib (Gleevec) in patients with the sarcoma known as gastrointestinal stromal tumor (GIST), one of the first examples of targeted cancer therapy for a treatment-resistant solid tumor.
Dr. Demetri's role at Dana-Farber is also complemented by serving as the co-director of the Ludwig Center at Harvard along with Joan Brugge, PhD, of Harvard Medical School, comprising more than 30 investigative teams collaborating across Harvard-affiliated
institutions to understand, overcome and prevent resistance of cancers to therapeutic interventions. Dr. Demetri trained at Harvard College and Stanford University School of Medicine, followed by internal medicine residency and chief residency at
the University of Washington Hospitals in Seattle. He also co-directs the Harvard Medical School Global Education course on Cancer Biology and Therapeutics.
Lisa R. Diller, MD
Chief Medical Officer, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Lisa R. Diller, MD, chief medical officer at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, is also the clinical director of Pediatric Oncology, and the medical director of the David B. Perini,
Jr. Quality of Life Clinic. Her research focuses on the late effects of treatment of childhood cancer and genetic cancer predispositions in childhood; her clinical work focuses on pediatric solid tumors. Dr. Diller received her bachelor’s degree from
Harvard University and earned her Doctor of Medicine from the University of California at San Diego.
Gerard M. Doherty, MD
Chair of Surgery
A graduate of College of the Holy Cross and Yale School of Medicine,
Gerard M. Doherty, MD, completed residency training at UCSF, including a fellowship at the National Cancer Institute. He joined Washington University School of Medicine in 1993, and became professor of
Surgery in 2001. In 2002 he was named head of General Surgery and Thompson Professor of Surgery at the University of Michigan, where he also served as General Surgery Program director and vice chair of the Department of Surgery. From 2012 to 2016,
Dr. Doherty was Utley Professor and Chair of Surgery at Boston University and surgeon-in-chief at Boston Medical Center, before becoming professor of Surgery at Harvard Medical School, and surgeon-in-chief at Brigham and Women’s Hospital.
Dr. Doherty has focused on surgical diseases of the thyroid, parathyroid, endocrine, pancreas, and adrenal glands, as well as the surgical management of MEN syndromes. He has devoted substantial effort to medical student and resident education policy.
His bibliography includes over 300 peer-reviewed articles, reviews, and book chapters, and several edited books.
He currently serves as president-elect of the International Association of Endocrine Surgeons, past-president of the American Association of Endocrine Surgeons, member of the Surgical Oncology Board of the American Board of Surgery (ABS), editor-in-chief
of VideoEndocrinology, and reviews editor of JAMA Surgery.
Senior Vice President, Chief Philanthropy Officer
Melany Duval joined Dana-Farber in 2019. Prior to this, she was Vice President of Development at Silicon Valley Community Foundation, the largest community foundation in the world. She also held positions as Senior Associate Dean and Associate Vice President
of Health Science Campus Development at the University of Southern California, and at Children’s Hospital of Los Angeles. Ms. Duval earned her bachelor’s degree in political science and business administration from Loyola Marymount University.
Benjamin Ebert, MD, PhD
Chair of Medical Oncology
Benjamin Ebert, MD, PhD, chair of Medical Oncology at Dana-Farber Cancer Institute, is professor of Medicine at Harvard Medical School, an institute member of the Broad Institute, and leader of the Leukemia
Program for the Dana-Farber/Harvard Cancer Center.
His research focuses on the genetics, biology, and therapy of myeloid malignancies. This work has led to the characterization of clonal hematopoiesis as a pre-malignant state for hematologic malignancies, and elucidation of the mechanism of action of
lenalidomide and related molecules that induce degradation of specific proteins.
Dr. Ebert received a bachelor's degree from Williams College, a doctorate from Oxford University on a Rhodes Scholarship, and an MD from Harvard Medical School. He completed a residency in internal medicine at Massachusetts General Hospital and a fellowship
in hematology/oncology at Dana-Farber.
Anne Gross, PhD, RN, NEA-BC, FAAN
Senior Vice President, Patient Care Services and Chief Nursing Officer
Anne Gross, PhD, RN, NEA-BC, FAAN, became Dana-Farber’s senior vice president for patient care services and chief nursing officer in 2016. She joined Dana-Farber in 2002 and since 2004 served as vice president, Adult Nursing and Clinical Services. Dr.
Gross is a Fellow of the American Academy of Nursing and currently serves as co-chair elect of the Academy’s Fellows Selection Committee. Prior to joining Dana-Farber, she was a clinical nurse and leader, most recently at Cambridge Health Alliance.
She received her bachelor's degree in nursing from St. Louis University, her master’s degree in nursing from Boston College, and her doctoral degree from the University of Massachusetts.
Daphne Haas-Kogan, MD
Professor and Chair, Department of Radiation Oncology
Dana-Farber Cancer Institute/Brigham and Women’s Hospital/Boston Children’s Hospital
Daphne Haas-Kogan, MD, received her medical degree from the University of California at San Francisco (UCSF) in 1991. She completed a research fellowship, followed by residency in radiation oncology at the
UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC). Dr. Haas-Kogan spent 18 years as a radiation oncologist, researcher, and academic leader in the UCSF HDFCCC system before becoming chair of the Department of Radiation Oncology at Dana-Farber,
Brigham and Women’s Hospital, and Boston Children’s Hospital in 2015.
Kevin M. Haigis, PhD
Chief Scientific Officer
Chair, Executive Committee for Research (ECR)
Kevin M. Haigis, PhD, joined Dana-Farber as Chief Scientific Officer in 2020. Prior to assuming this role, Dr. Haigis was Director of Cancer Genetics at Beth Israel Deaconess Cancer Center. Dr. Haigis received his PhD in genetics from the University of
Wisconsin-Madison and did post-doctoral work at the Massachusetts Institute of Technology, where he was a Robert Black Fellow of the Damon Runyon Cancer Research Foundation.
Dr. Haigis has a long-standing interest in intestinal biology and the molecular pathogenesis of colorectal cancer. His laboratory combines computational and informatic approaches with experimental approaches in genetically engineered mice to study the
relationship among Ras oncogene signaling, colorectal cancer, and inflammation.
Rafael Irizarry, PhD
Chair, Department of Data Science
Rafael Irizarry, PhD, received his Bachelor's degree in Mathematics in 1993 from the University of Puerto Rico, and went on to receive a PhD in Statistics in 1998 from the University of California, Berkeley.
His thesis work was on Statistical Models for Music Sound Signals. He joined the faculty of the Johns Hopkins Department of Biostatistics in 1998, and was promoted to Professor in 2007. He is now Professor and Chair of the Department of Data Science
at Dana-Farber, and a Professor of Biostatistics at Harvard School of Public Health.
Professor Irizarry's dedication to education is best demonstrated by the success of the numerous trainees he has mentored. He has also developed several HarvardX online courses on data analysis, which have been completed by thousands of students. These
courses are divided into three series: Professional Certificate in Data Science, Data Analysis for the Life Sciences, and Genomics Data Analysis. He shares the material for these courses through textbooks that are freely available online and reproducible
code through GitHub.
Bruce E. Johnson, MD
Senior Advisor to the President
Bruce E. Johnson, MD, was Dana-Farber’s chief clinical research officer from 2013 until 2021. He previously was director of the Lowe Center for Thoracic Oncology at Dana-Farber Brigham Cancer Center. He is
also professor of Medicine at Harvard Medical School and an American Society of Clinical Oncology translational research professor. Dr. Johnson is serving as co-director of the Center for Cancer Genomics (CCG).
Dr. Johnson graduated from Harvard University and the University of Minnesota Medical School. His postdoctoral training was at the University of Chicago Hospitals and Clinics and the National Cancer Institute. In 1992, he became head of the Lung Cancer
Biology Section, Medicine Branch, at the NCI, until 1998, when he joined Dana-Farber. Dr. Johnson is currently serving as president of the American Society of Clinical Oncology.
Dr. Johnson directs the Lung Cancer Program within the Dana-Farber/Harvard Cancer Center. His translational research is devoted to testing novel therapeutic agents for their efficacy against lung cancer and other thoracic malignancies with specific genomic
Jason M. Johnson, PhD
Senior Vice President, Chief Data and Analytics Officer
Jason M. Johnson, PhD, joined the Institute in April 2016 and serves as chief health information officer. Prior to joining Dana-Farber, Dr. Johnson was executive vice president and head of R&D at PatientsLikeMe, a patient-focused research company in Cambridge,
MA. He came to that position after serving in various leadership roles in scientific informatics, bioinformatics, and genomics at Merck for many years. Dr. Johnson holds AB and BS degrees from Stanford University, a master’s degree from the University
of Cambridge (UK), and a PhD in Biophysics from Harvard University.
Christopher S. Lathan, MD, MS, MPH
Chief Clinical Access and Equity Officer
Christopher S. Lathan, MD, MS, MPH, is Dana-Farber's Chief Clinical Access and Equity Officer. He is also associate medical director of the Dana-Farber Cancer Institute Network, and assistant professor
of Medicine at Harvard Medical School. Dr. Lathan's primary research interests are centered on the effects of race, class, and access to care in cancer outcomes, including racial disparities in lung cancer treatment, differences in access to precision
medicine by race and social class, and equitable distribution of new treatment across vulnerable populations.
Dr. Lathan aims to bridge the gap between research efforts in disparities and the realities of patient care by developing interventions to increase access to high quality care, developed in part through community engagement. He remains a clinical oncologist
focusing on lung cancer patients and is the founding director of Dana-Farber's Cancer Care Equity Program, a clinical outreach program that aids in the diagnosis and treatment of cancer for patients at Federally Qualified Health Centers. He is also
the associate director of the Dana-Farber Network, with a focus on the accessibility of clinical trials.
Vice President, Chief Inclusion, Diversity, and Equity Officer
Ian Matthew-Clayton joined Dana-Farber in 2022. He joined Dana-Farber from Johns Hopkins University, where he served as Executive Director for Talent Acquisition and as a Human Resources Leadership Team member.
Mr. Matthew-Clayton is a proven leader in recruiting and supporting diverse talent and leading strategic initiatives rooted in inclusion, diversity, and equity. He led the development of new resources for hiring managers to reduce unconscious bias in
the recruiting process, as well as resources for employees to support their career development and advancement.
Notably, Mr. Matthew-Clayton played a vital role in the Johns Hopkins Roadmap 2020 Taskforce that oversaw the university's commitment to diversity, equity, and inclusion. Prior to his work at Johns Hopkins, Mr. Matthew-Clayton served as Director of Talent
Acquisition and Recruitment at the George Washington University, as well as Director of Human Resources Operations at the City College of New York. He earned his BA from the University at Buffalo and holds an MSEd from Fordham University.
Kelly M. Maxwell, Esq.
Vice President, Chief Compliance Officer
Kelly Maxwell, Esq., is currently Dana-Farber's Vice President, Chief Compliance Officer. She has served in this role for nearly 10 years. Prior to joining Dana-Farber, Ms. Maxwell was Counsel in Akin Gump Strauss Hauer & Feld's health industry practice
in Washington, DC, for almost eight years. She focused on health care regulatory, reimbursement, compliance, and government investigations — working collaboratively with several practice areas throughout the firm. For two years prior, she was a Senior
Government Relations Associate with a boutique advocacy shop focused primarily on urban hospital matters. Ms. Maxwell started her professional career working for Congressman Robert A. Borski from Philadelphia, PA, for five years, serving finally as
Legislative Director. She is an alumna of Catholic University School of Law, and is a zealous advocate of Institute integrity and incorporating inclusion, diversity, and equity into the fabric of her work.
Senior Vice President, Chief Administrative Officer
Maria Megdal oversees day-to-day clinical operations throughout the enterprise, including adult and pediatric ambulatory care operations, radiation oncology, imaging, clinical laboratory, cell therapy manufacturing and transplant administration, and inpatient
services. Additionally, Ms. Megdal is responsible for facilities management and real estate, supply chain management, and the Friends of Dana-Farber.
Ms. Megdal joined Dana-Farber as vice president of facilities management and real estate in 2008, spearheading construction and opening of the Yawkey Center for Cancer Care in 2011 and executing on development initiatives more than doubling the physical
size of the Institute. She previously served as vice president of real estate development at Saint Vincent Catholic Medical Centers of New York and in various roles at Memorial Sloan Kettering Cancer Center following completion of their administrative
Ms. Megdal holds a bachelor's degree in physical anthropology from Rutgers University and a master's degree from the Sloan Program in Healthcare Administration at Cornell University, where she also serves as an adjunct lecturer on strategy and facilities
Jeffrey A. Meyerhardt, MD, MPH, FASCO
Chief Clinical Research Officer
Jeffrey A. Meyerhardt, MD, MPH, FASCO, is the Chief Clinical Research Officer at Dana-Farber Cancer Institute and the Associate Director of Clinical Research at Dana-Farber/Harvard Cancer Center. Dr.
Meyerhardt earned his medical degree from Yale University School of Medicine, and completed an internship and residency in Medicine at Beth Israel Deaconess Medical Center. He completed a clinical fellowship in Medical Oncology at Dana-Farber Cancer
Institute and Massachusetts General Hospital.
Dr. Meyerhardt also holds a Master's of Public Health from Harvard School of Public Health. He is a Senior Physician in Dana-Farber Brigham Cancer Center's Gastrointestinal Cancer Treatment Center; holds the Douglas Gray Woodruff Chair in Colorectal Cancer
Research; and is a Professor of Medicine at Harvard Medical School.
Lee M. Nadler, MD
Senior Vice President, Experimental Medicine
Lee M. Nadler, MD, received his medical degree from Harvard Medical School in 1973. After residency training at Columbia-Presbyterian Medical Center, and training at the National Cancer Institute in tumor immunology,
he completed a medical oncology fellowship at Dana-Farber, where he joined the staff in 1980. During his tenure at Dana-Farber, he has served as chief of the Division of Hematologic Malignancies and was the first chair of the Department of Adult Oncology.
Dr. Nadler is the Virginia and D.K. Ludwig Professor of Medicine at Harvard Medical School and the Pan-Mass Challenge Chair at Dana-Farber.
Senior Vice President for External Affairs
Caroline Powers joined Dana-Farber in 2021. Previously, she was senior director for federal relations at the American Cancer Society Cancer Action Network (ACS CAN). She has also served as senior advisor for federal-state relations with a focus on health
policy to Massachusetts Governor Deval Patrick, and as legislative director in the U.S. House of Representatives for Congressman Stephen F. Lynch. Ms. Powers began her career as a health policy analyst in the Massachusetts State Senate. She has a
master’s degree in Government from the Johns Hopkins University and a B.A. in American Studies from Goucher College, both in Baltimore, MD.
Barrett J. Rollins, MD, PhD
Linde Family Professor of Medicine, Harvard Medical School
Barrett J. Rollins, MD, PhD, received his doctoral degree in 1979 and medical degree in 1980 from Case Western Reserve University and completed his internship and residency in internal medicine at Beth Israel
Hospital, Boston. He then performed clinical and research fellowships in medical oncology at Dana-Farber and joined the Institute's faculty in 1986. Dr. Rollins served as Dana-Farber's Chief Scientific Officer from 2004-2019; he is currently Professor
of Medicine at Harvard Medical School and a senior advisor to Dana-Farber's President and CEO.
Stephen E. Sallan, MD
Chief of Staff Emeritus
Stephen E. Sallan, MD, joined the Institute in 1973 as a trainee before becoming a member of the staff in the Department of Pediatric Oncology. He was named chief of staff and chairman of the Medical Staff
Executive Committee in 1995, and chief of staff emeritus in 2012. Dr. Sallan received his undergraduate and medical degrees from Wayne State University. He is presently a professor of Pediatrics at Harvard Medical School, and was named the Quick Family
Senior Investigator in 2002.
Atul Shinagare, MD
Interim Chair, Department of Imaging
Atul Shinagare, MD, has been part of the radiology team at Dana-Farber Brigham Cancer Center since July 2009. He is fellowship-trained in cancer imaging, abdominal imaging, and
informatics, and his areas of clinical and research interests include genitourinary cancers and improving the quality of radiology reports. Dr. Shinagare is a prolific researcher with an extensive track record of high-impact publications, mentorship
skills, and collaborations both within and beyond Dana-Farber Brigham Cancer Center. He has served as Dana-Farber's Radiology Quality and Safety Officer and Associate Program Director of the Cancer Imaging fellowship program. Currently he is associate
professor of Radiology at Harvard Medical School.
Dr. Shinagare has received numerous awards, including the Radiological Society of North America (RSNA) Honored Educator award and the RSNA Research Scholar grant. He is the fellow of the Society of Abdominal Radiology, serves as associate editor for Abdominal Radiology,
and is the section editor for Cancer Imaging.
Robert J. Soiffer, MD
Chair, Executive Committee for Clinical Programs (ECCP)
Robert J. Soiffer, MD, is professor of Medicine at Harvard Medical School and institute physician at Dana-Farber. He is chief of the Division of Hematologic Malignancies, vice-chairman of Medical Oncology,
and co-director of the Bone Marrow Transplant Service at Dana-Farber. He serves on the Executive Committee for Clinical Practice, the Executive Committee for Clinical Research, and the Executive Patient Safety Oversight Group at Dana-Farber.
Dr. Soiffer is a former president of the American Society for Blood and Marrow Transplantation. He served on the advisory board for the Center for International Blood and Marrow Transplant Research. He is a member of the executive steering committees
for the Blood and Marrow Transplant Clinical Trials Network; serves on the board of directors for the National Marrow Donor Program Be the Match Registry; and serves on the board of the Massachusetts chapter of the Leukemia & Lymphoma Society.
Richard Stone, MD
Chief of Staff
Professor of Medicine, Harvard Medical School
Richard Stone, MD, is director of Dana-Farber's Adult Acute Leukemia Program. Dr. Stone is nationally recognized for his translational and clinical research concerning blood and bone marrow malignancies, including
acute leukemia, myeloproliferative disorders, and myelodysplastic syndrome (MDS), a bone marrow failure state that may convert to leukemia.
In addition to his work at Dana-Farber, Dr. Stone serves as chair of the Medical Oncology Board of the American Board of Internal Medicine, chair of the Medical Advisory Board of the Aplastic Anemia & MDS International Foundation, and chairman of the
Leukemia Core Committee for the Alliance for clinical Trials in Oncology.
Dr. Stone earned his medical degree from Harvard Medical School in 1981. He completed his internal medicine residency training at Brigham and Women's Hospital and his hematology-oncology fellowship at Dana-Farber.
Mary-Ellen Taplin, MD
Chair, Executive Committee for Clinical Research (ECCR)
Mary-Ellen Taplin, MD, joined the Institute in 2003. She serves as director of clinical research for the Lank Center for Genitourinary Oncology at Dana-Farber /Brigham and Women’s Cancer Center. She is also
professor of Medicine at Harvard Medical School. She is an investigator on many projects, including the Prostate Cancer Clinical Trial Consortium, Dana-Farber SPORE grant, Stand Up 2 Cancer, and several Prostate Cancer Foundation Challenge Grants.
Dr. Taplin has been dedicated to clinical and translational investigations that focus on novel approaches to treating localized high risk prostate cancer and secondary hormone therapy for metastatic castration-resistant prostate cancer. She has described
molecular and physiologic alterations in the androgen receptor pathway in the context of prostate cancer resistance. Dr. Taplin is dedicated to patient care and clinical investigation in genitourinary oncology.
Senior Vice President, Chief Communications and Marketing Officer
Goldie Taylor joined the Institute in 2022. She previously served as chief marketing officer at Morehouse School of Medicine. Well-known for her on-air and leadership roles at CNN and NBC News, Ms. Taylor has also held senior and executive positions in
the private and public sectors, including Edelman Public Relations, Metropolitan Atlanta Rapid Transit Authority, NBC Universal, and Burrell Communications. Among other leadership positions, Ms. Taylor has directed strategic communications and marketing
campaigns for the Centers for Disease Control and Prevention, McDonald's, Kraft Foods, The Home Depot, Toyota North America, Rollins School of Public Health at Emory University, and the Procter & Gamble family of brands.
Mary Tolikas, PhD, MSc, MBA
Senior Vice President and Chief Innovation Officer
Mary Tolikas, PhD, MSc, MBA, joined Dana-Farber in 2022. Dr. Tolikas has more than two decades of experience in establishing and growing technology-based organizations in both industry and academia. Prior to joining Dana-Farber, she was CEO of the Wyss
Center for Bio and Neuroengineering in Geneva, Switzerland, where she led the Center's business operations, and managed the development and translation of projects that span neurotechnology, neuroradiology, and neurobiology modalities.
Dr. Tolikas also played a central role in the launch and growth of the Wyss Institute for Biologically Inspired Engineering at Harvard University, where she spent nearly 10 years on the leadership team as Operations Director. At Harvard, she also served
as Executive Director for Special Projects in the Office of the Provost, and was co-instructor in the Master in Design Engineering Program.
Dr. Tolikas holds a BEng degree in Electrical and Electronics Engineering from the University of Glasgow, Scotland, MSc and PhD degrees in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology (MIT), and an MBA from
the Sloan School of Management at MIT.
James Tulsky, MD
Chair, Department of Psychosocial Oncology and Palliative Care
James Tulsky, MD, received his AB from Cornell University, his MD from the University of Illinois College of Medicine at Chicago, and completed internal medicine training at the University of California, San
Francisco (UCSF). He continued at UCSF as chief medical resident and subsequently as a Robert Wood Johnson Clinical Scholar. Dr. Tulsky was on the faculty of Duke University from 1993-2015, lastly as professor of Medicine and Nursing and chief, Duke
Palliative Care. He joined Dana-Farber Cancer Institute in 2015 to be Chair, Department of Psychosocial Oncology and Palliative Care. Dr. Tulsky has a longstanding research interest in clinician-patient communication and quality of life in serious
Jennifer Willcox, JD
Senior Vice President, General Counsel and Chief Governance Officer
Jennifer Willcox, JD, joined Dana-Farber in June 2022 as SVP, General Counsel and Chief Governance Officer. She joined from Yale New Haven Health (YNHH), where she served as Vice President of Legal Services. At YNHH, Ms. Willcox provided corporate, litigation,
clinical risk management, patient care regulatory, employment, and labor advice for the health system that employs more than 25,000 people and includes five hospitals and a medical foundation with 1,000 physicians.
As a leader committed to diversity and health equity, Ms. Willcox helped establish the first "Medical Legal Partnership" at YNHH and led ongoing department initiatives to improving the hiring of diverse attorneys at partner firms. Previously in her career,
she was also a partner in the healthcare department of Pullman & Comley, representing hospitals, academic medical centers, and other health care organizations. Ms. Willcox earned a bachelor’s degree from Yale University and a Juris Doctor degree from
Northeastern University School of Law.
David A. Williams, MD
Associate Chair, Department of Pediatric Oncology
David A. Williams, MD, is chief of Hematology/Oncology and director of Clinical and Translational Research at Boston Children’s Hospital and associate chairman, Department of Pediatric Oncology at Dana-Farber
Cancer Institute. He is director of the Pediatric Hematology/Oncology Fellowship Training Program at Dana-Farber/Boston Children's.
Dr. Williams' laboratory has been continuously NIH-funded since 1986. He has served on multiple NIH Study Sections, including currently on the Loan Repayment Study Section for Pediatrics; he served for five years on the NCI Parent Committee for Comprehensive
Cancer Centers. Dr. Williams served on both the Recombinant DNA Advisory Committee (RAC) and the NIH Gene Therapy Safety Advisory Board. He is a past President of the American Society of Hematology. He has trained over 45 fellows and post-doctoral
fellows and numerous residents and medical students in his laboratory, the majority of whom are still in academic medicine.
Dr. Williams is a member of the National Academy of Sciences. He has published over 250 peer-reviewed manuscripts, over 100 invited reviews, and multiple textbook chapters. He is actively involved in gene therapy trials for blood, immunodeficiency, and
neurological genetic diseases.
Kai Wucherpfennig, MD, PhD
Chair, Department of Cancer Immunology and Virology
Kai Wucherpfennig, MD, PhD, is chair of the Department of Cancer Immunology and Virology at Dana-Farber, and Professor of Neurology and Professor of Immunology at Harvard Medical School. He is also a co-leader
of the Cancer Immunology Program of Dana-Farber/Harvard Cancer Center.
Dr. Wucherpfennig's research focuses on the role of cytotoxic T cells and NK cells in cancer immunotherapy. His lab has defined key negative regulators of T cell function in the tumor microenvironment that represent novel therapeutic targets. He has also
discovered molecular mechanisms in cancer cells responsible for resistance to T cell-mediated cytotoxicity.
He has been elected as a member of the American Society for Clinical Investigation (2006), the Henry Kunkel Society at Rockefeller University (2007), and as Fellow of the American Society for the Advancement of Science (2009). Dr. Wucherpfennig received
MD and PhD degrees from the University of Göttingen in Germany, and did his postdoctoral training at Brigham and Women's Hospital and at Harvard College.